LENZ Therapeutics, Inc. commercializes VIZZ (aceclidine ophthalmic solution) 1.44%, an FDA-approved aceclidine-based prescription eye drop for the treatment of presbyopia in adults. Company news centers on U.S. commercialization, product availability, financial results, prescribing and product-revenue updates, and consumer and professional education for the ophthalmic product.
Recurring LENZ developments also include regulatory submissions for VIZZ outside the United States, international licensing and commercialization partnerships, investor-conference participation, and safety or pharmacovigilance communications related to real-world product use. VIZZ is described by the company as a once-daily, preservative-free, single-dose vial product that uses a predominantly pupil-selective miotic mechanism to improve near vision.
LENZ Therapeutics (LENZ) reported third-quarter VIZZ product sales of $2.6 million and announced a reorganization focused on consumer marketing. Sales increased 50% over the prior quarter, with over 38,000 paid prescriptions. Total revenue was $3.384 million versus $12.5 million a year earlier, while net loss widened to $31.0 million from $16.7 million.
The company expects the reorganization to reduce projected 2027 annualized operating expenses by more than 50%, targeting approximately $70 million to $75 million, excluding stock-based compensation. It anticipates substantially completing the work in Q4 2026, with estimated one-time net restructuring charges of $5 million. CFO Dan Chevallard will become interim president and CEO on December 1, 2026, succeeding Eef Schimmelpennink, who will remain a strategic advisor into 2027. Cash, cash equivalents and marketable securities totaled $197.3 million at September 30, 2026.
LENZ Therapeutics (LENZ) will report its third quarter 2026 financial results during a webcast on October 29, 2026. The webcast begins at 8:30 a.m. EDT and will be accessible through the Investors & Media section of the company’s website. A replay will remain available for 30 days following the event.
LENZ Therapeutics (Nasdaq: LENZ) reported Q2 2026 total revenue of $5.5 million, including $1.7 million in VIZZ product sales from roughly 27,000 packs and $3.8 million in license revenue, driven by milestone and sublicense payments. VIZZ has seen strong early adoption, with over 13,000 unique prescribers since launch and more than 60% of ePharmacy patients purchasing multiple monthly packs, tracking to about five packs annually in early cohorts.
LENZ expanded its ex‑U.S. footprint with new or advanced agreements in Australia/New Zealand, Canada, Greater China and Saudi Arabia, and now has nine ex‑U.S. regulatory filings. Q2 SG&A rose to $39.4 million on launch spending, there was no R&D expense after FDA approval, and net loss widened to $31.9 million. Cash, cash equivalents and marketable securities totaled $220.0 million at June 30, 2026.
LENZ Therapeutics (Nasdaq: LENZ), a pharmaceutical company focused on commercializing VIZZ® (aceclidine ophthalmologic solution) 1.44%, the first FDA-approved aceclidine-based eye drop for presbyopia in adults, will host a webcast on Tuesday, August 11, 2026, at 4:30 p.m. EDT to report its second quarter 2026 financial results and discuss recent corporate highlights.
Investors can join via telephone at (800) 715-9871 (Domestic) or (646) 307-1963 (International) using access code 2922111, or via live webcast on the LENZ Therapeutics website in the Investors & Media section. A replay will be available online for 30 days.
LENZ Therapeutics (Nasdaq: LENZ) launched a new telehealth prescribing option for VIZZ, its aceclidine ophthalmic solution 1.44% for presbyopia. The platform at VIZZ.com connects patients with independent licensed eye care providers for online evaluations, e-pharmacy prescription fulfillment, and home delivery.
The telehealth launch is being promoted alongside LENZ’s nationwide ‘Tired of Reading Glasses’ TV and digital campaign featuring brand spokesperson Sarah Jessica Parker, which the company expects to support awareness, access, and adoption of VIZZ.
LENZ Therapeutics (Nasdaq: LENZ) and Arrotex Pharmaceuticals signed an exclusive license and commercialization deal for VIZZ in Australia and New Zealand. LENZ receives an upfront payment plus a significant profit share of gross margin, while Arrotex gains exclusive rights to register and commercialize VIZZ for presbyopia.
VIZZ (aceclidine ophthalmic solution 1.44%) is described as the first and only FDA-approved aceclidine-based eye drop for presbyopia, approved in July 2025 and commercially available in the United States since October 2025. LENZ describes this as its fifth ex-US commercialization partnership for VIZZ.
LENZ Therapeutics (Nasdaq: LENZ) announced that Everest Medicines acquired rights to develop, manufacture and commercialize VIZZ (LNZ100) for presbyopia in Greater China.
LENZ may receive up to $85 million in remaining milestones, additional payments, and tiered mid single-digit to low double-digit royalties on net sales.
LENZ Therapeutics (Nasdaq: LENZ), focused on commercializing VIZZ (aceclidine ophthalmologic solution) 1.44% for presbyopia in adults, will participate in three upcoming investor conferences. Management will host 1x1 investor meetings in Chicago on June 2, New York on June 3, and Miami on June 9, 2026.
LENZ Therapeutics (Nasdaq: LENZ) reported Q1 2026 revenue of $1.9 million, including $1.7 million in VIZZ sales on about 25,000 paid prescriptions. From launch through Q1, about 46,000 prescriptions were filled by over 10,000 eye care professionals. Cash was $258.4 million; net loss was $41.5 million.
LENZ Therapeutics (Nasdaq: LENZ) will report first quarter 2026 financial results and corporate highlights via a live webcast on May 11, 2026 at 4:30 p.m. EDT. The company commercializes VIZZ® (aceclidine ophthalmologic solution) 1.44%, indicated for presbyopia in adults.
Management will also hold one-on-one meetings at the Bank of America Global Healthcare Conference on May 13–14, 2026 in Las Vegas. A webcast replay will be available on the company website for 30 days.